Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Endocrine Surgery
  •  Bariatric Surgery
  •  Urology
  •  Emergency Surgery
  •  Plastic Surgery
  •  Colon and Rectal Surgery
  •  Orthopaedic Surgery
  •  Oral and Maxillofacial Surgery


Citation: Clin Surg. 2019;4(1):2438.Research Article | Open Access

Parecoxib Prevents Postoperative Pain after Radiofrequency Ablation for Liver Cancer: A Propensity Score Matching Analysis

Jian-Cong Chen, Jun-Cheng Wang, Yao-Jun Zhang, Li Xu, Jin-Bin Chen, Yang-Xun Pan, Ying-Qin Zhu, Min-Shan Chen and Zhong-Guo Zhou

Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, China
Both authors contributed equally to this work

*Correspondance to: Zhong-Guo Zhou 

 PDF  Full Text DOI: 10.25107/2474-1647.2438


Background: Pain is one of the most dominating adverse effects in radiofrequency ablation therapy. The purpose of this study is to evaluate the role of parecoxib sodium on pain management in patients with liver cancer undergoing radiofrequency ablation.
Methods: A total of 186 patients diagnosed as liver cancer (including primary cancer 122 cases and metastasis lesion 64 cases) and treated with radiofrequency ablation at Sun Yat-sen University Cancer Center between April 2015 and January 2016 were retrospectively reviewed. About 111 patients achieved the inclusion criteria and were divided into the parecoxib group (experimental group; n=56) and the non-parecoxib group (control group, receiving 0.9% sodium chloride; n=55), according to whether or not the medication was applied. Post-operative pain, vomiting, body temperature, changes in hepatic function, and duration of postoperative hospitalization time were compared between the two groups.
Results: After the propensity score matching analysis, the parecoxib group had suffered less severe pain on postoperative day 0, day 1 and day 2 (with P<0.000, 0.001 and 0.0041, respectively), compared with the non-parecoxib one, along with a lower ALT and CRP levels (177.0 ± 88.0 vs. 327.7 ± 387.1 U/L, P<0.016, and 20.0 ± 29.0 vs. 49.7 ± 44.1 mg/L, P<0.001, respectively), and an insignificant shorter postoperative hospitalization time was witnessed, though not significantly (2.4 ± 0.7 vs. 2.6 ± 0.6 days, P=0.186).
Conclusion: This research illustrated that the preemptive application of parecoxib can remarkably relieve postoperative discomfort, especially controlling post-operative pain, reducing hepatic inflammation, and shortening post-operative hospital stay after radiofrequency ablation for liver cancer.


Parecoxib; Postoperative complication control; Pain management; Radiofrequency ablation

Cite the article

Chen J-C, Wang J-C, Zhang Y-J, Xu L, Chen J-B, Pan Y-X, et al. Parecoxib Prevents Postoperative Pain after Radiofrequency Ablation for Liver Cancer: A Propensity Score Matching Analysis. Clin Surg. 2019; 4: 2438.

Search Our Journal

Journal Indexed In

Articles in PubMed

Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
Automated Sagittal Craniosynostosis Classification from CT Images Using Transfer Learning
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Prognosis of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty versus Bare Nitinol Stent Angioplasty for Femoropopliteal Arteriosclerosis Obliterans: A Retrospective Cohort Study
 Abstract  PDF  Full Text
Set Up New Cardiac Surgery Peri-Operative Service in a General Adult Intensive Care Unit during COVID-19 Pandemic
 Abstract  PDF  Full Text
View More...